Retatrutide 64mg Multi-Dose Injection Pen

R 4,480.00
Add to WishlistCompare

BodyPharm's Retatrutide 64mg pen is a pre-filled, multi-dose subcutaneous delivery device formulated for laboratory and clinical research applications involving triple hormone receptor agonism. Each pen contains 64mg of retatrutide (LY3437943), a compound that simultaneously targets the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors — a mechanism of particular interest to researchers studying incretin-based metabolic pathways, energy expenditure, and glycemic regulation.

The pen is formulated with disodium phosphate dihydrate, propylene glycol, phenol, and sterile water as excipients, supporting compound stability across the research handling process. Its multi-dose design (with clearly marked 2mg, 4mg, and 8mg dial increments) allows research teams to standardize dosing across study protocols without needing to reconstitute or measure from a vial, reducing variability introduced by manual preparation.

Each unit is single-patient/single-subject use only, and ships in tamper-evident packaging with a batch reference (EU-0344-LAB4 Rv1.1) for traceability — an important consideration for institutions maintaining chain-of-custody documentation for research compounds.

Retatrutide has drawn significant attention in metabolic research circles following Phase 2 and Phase 3 clinical trial data published in journals including the New England Journal of Medicine and Nature Medicine, which reported substantial effects on body weight, liver fat, and glycemic markers in trial populations. BodyPharm's research-grade formulation is intended to support continued investigation into these mechanisms by qualified laboratories, academic institutions, and licensed investigators.

Key Features
  • Format: Pre-filled multi-dose subcutaneous injection pen
  • Concentration: 64mg retatrutide per pen (dial settings shown: 2mg / 4mg / 8mg increments)
  • Excipients: Disodium phosphate dihydrate, propylene glycol, phenol, sterile water
  • Use restriction: Single patient/single research subject use only
  • Packaging: Boxed pen with tamper-evident seal, lot/batch reference (EU-0344-LAB4 Rv1.1)
  • Manufacturer: BodyPharm
Dosage & Usage

Retatrutide is a triple receptor agonist that targets:


  • GLP-1 (Glucagon-Like Peptide-1)

  • GIP (Glucose-Dependent Insulinotropic Polypeptide)

  • Glucagon receptors

This combination is being investigated for its effects on:


  • Body weight regulation

  • Appetite signaling

  • Energy expenditure

  • Glucose metabolism

  • Cardiometabolic health

Research Status


  • Investigational compound

  • Currently undergoing Phase 3 clinical evaluation

  • Not approved by major regulatory authorities for routine clinical use

Research Considerations

Research involving Retatrutide generally evaluates outcomes such as:


  • Changes in body weight

  • Glycemic markers

  • Waist circumference

  • Lipid profiles

  • Cardiometabolic biomarkers

  • Safety and tolerability

Researchers typically monitor participants throughout studies for adverse events, laboratory parameters, and changes in metabolic health.

Storage


  • Store according to the manufacturer's recommendations.

  • Protect from excessive heat and direct sunlight.

  • Do not use if the device appears damaged or compromised.

References


  • Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 2023.

  • ClinicalTrials.gov – Ongoing Retatrutide Phase 3 Clinical Studies.
FAQ's & Tips

Q: Is this product approved for human use?

A: No. Retatrutide is an investigational compound currently in Phase 3 clinical trials and is not approved by the FDA, EMA, or any regulatory body for human treatment. This product is sold for research purposes only.

Q: Who can purchase this product?

A: This listing is intended for qualified researchers, laboratories, and institutions conducting legitimate scientific research — not for personal or clinical use.

Q: How should the pen be stored?

A: Store according to the manufacturer's cold-chain guidelines (refrigerated, protected from light). Refer to the product insert for exact storage specifications, as peptide compounds are typically temperature-sensitive.

Q: What's included in the box?

A: One 64mg multi-dose retatrutide pen with excipient information printed on the packaging.

Q: Is this the same formulation used in Eli Lilly's clinical trials?

A: This is a third-party manufactured research compound. It is not sourced from or affiliated with Eli Lilly, the company developing retatrutide (LY3437943) in its official clinical trial program.

Research

Retatrutide (also known as LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly, targeting the GIP, GLP-1, and glucagon receptors simultaneously. It has been studied primarily in the context of obesity and type 2 diabetes.

Key published findings from Lilly's trials:

  • A Phase 2 obesity trial published in the New England Journal of Medicine found participants receiving the highest doses achieved mean weight reductions of up to 17.5% at 24 weeks, with reductions reaching up to 24.2% by 48 weeks. Eli Lilly and Company
  • The 338-participant trial randomized adults with obesity but without type 2 diabetes to 1mg, 4mg, 8mg, or 12mg doses, or placebo, over 48 weeks. ADA Meeting News
  • A related Phase 2a substudy found retatrutide produced dose-dependent reductions in liver fat, with the 8mg and 12mg doses reducing liver fat by roughly 81–82% relative to baseline at 24 weeks. nih
  • In diabetes-specific trials, 281 participants with type 2 diabetes were studied, and a 2026 Phase 3 trial reported A1C reductions of 1.7–2.0% and weight loss averaging 16.8% at the 12mg dose after 40 weeks, with no plateau observed. ADA Meeting Newsbarchart
  • Retatrutide is currently being evaluated in Lilly's Phase 3 TRIUMPH trial program across obesity, type 2 diabetes, knee osteoarthritis, sleep apnea, chronic low back pain, cardiovascular/renal outcomes, and fatty liver disease. Lilly is explicit that retatrutide remains investigational and is legally available only to participants enrolled in its clinical trials.
Reviews